Development of Fixed Dose Combination Products Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy

Vista sencilla de ítem
dc.contributor.authorHens, Bart
dc.contributor.authorCorsetti, Maura
dc.contributor.authorBermejo, Marival
dc.contributor.authorLöbenberg, Raimar
dc.contributor.authorGonzález, Pablo M.
dc.contributor.authorMitra, V
dc.contributor.authorDesai, Divyakant
dc.contributor.authorMurthy Chilukuri, Dakshina
dc.contributor.authorAceituno, Alexis
dc.date.accessioned2022-11-30T02:46:26Z
dc.date.available2022-11-30T02:46:26Z
dc.date.issued2019
dc.description.abstractThe gastrointestinal (GI) tract is one of the most popular and used routes of drug product administration due to the convenience for better patient compliance and reduced costs to the patient compared to other routes. However, its complex nature poses a great challenge for formulation scientists when developing more complex dosage forms such as those combining two or more drugs. Fixed dose combination (FDC) products are two or more single active ingredients combined in a single dosage form. This formulation strategy represents a novel formulation which is as safe and effective compared to every mono-product separately. A complex drug product, to be dosed through a complex route, requires judicious considerations for formulation development. Additionally, it represents a challenge from a regulatory perspective at the time of demonstrating bioequivalence (BE) for generic versions of such drug products. This report gives the reader a summary of a 2-day short course that took place on the third and fourth of November at the Annual Association of Pharmaceutical Scientists (AAPS) meeting in 2018 at Washington, D.C. This manuscript will offer a comprehensive view of the most influential aspects of the GI physiology on the absorption of drugs and current techniques to help understand the fate of orally ingested drug products in the complex environment represented by the GI tract. Through case studies on FDC product development and regulatory issues, this manuscript will provide a great opportunity for readers to explore avenues for successfully developing FDC products and their generic versions.en_ES
dc.facultadFacultad de Farmaciaen_ES
dc.file.nameHenz_Dev2019.pdf
dc.identifier.citationHens, B., Corsetti, M., Bermejo, M. et al. “Development of Fixed Dose Combination Products” Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy. AAPS J 21, 75 (2019). https://doi.org/10.1208/s12248-019-0346-6en_ES
dc.identifier.doihttps://doi.org/10.1208/s12248-019-0346-6
dc.identifier.urihttp://repositoriobibliotecas.uv.cl/handle/uvscl/7369
dc.languageen
dc.publisherSpringer
dc.sourceThe AAPS Journal
dc.subjectBIOEQUIVALENCEen_ES
dc.subjectFIXED DOSE COMBINATION DRUG PRODUCTSen_ES
dc.subjectFORMULATION PREDICTIONen_ES
dc.subjectIN VIVO PREDICTIONSen_ES
dc.subjectGASTROINTESTINAL PHYSIOLOGYen_ES
dc.titleDevelopment of Fixed Dose Combination Products Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy
dc.typeArticulo

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Henz_Dev2019.pdf
Tamaño:
1.11 MB
Formato:
Adobe Portable Document Format
Descargar

Colecciones

Artículos investigadores UV